COVID-19 and Anti-CD14 Treatment Trial

NCT04391309 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

49

Enrollment

NIH

Sponsor class

Stopped Stopped to slow rate of enrollment

Conditions

Coronavirus Disease 2019 (COVID-19)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Interventions

BIOLOGICAL: anti-CD14
OTHER: Placebo
DRUG: remdesivir

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]